These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

731 related items for PubMed ID: 9627539

  • 21. Atorvastatin plus pravastatin for the treatment of heterozygous familial hypercholesterolaemia--a pilot study.
    Athyros VG, Papageorgiou AA, Demitriadis DS, Kontopoulos AG.
    Curr Med Res Opin; 2001; 17(4):267-72. PubMed ID: 11922400
    [Abstract] [Full Text] [Related]

  • 22. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 23. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.
    Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C, European Consensus Panel on HDL-C.
    Curr Med Res Opin; 2004 Aug; 20(8):1253-68. PubMed ID: 15324528
    [Abstract] [Full Text] [Related]

  • 24. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S, Schuster H, Barter P, Watkins C, Kallend D, MERCURY I Study Group.
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [Abstract] [Full Text] [Related]

  • 25. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE, Feely J, Sigurdsson EL, DISCOVERY study group.
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [Abstract] [Full Text] [Related]

  • 26. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, Nayak UP, Sharma A, Bolmall C, Baliga VP.
    J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
    [Abstract] [Full Text] [Related]

  • 27. Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification.
    Sang ZC, Wang F, Zhou Q, Li YH, Li YG, Wang HP, Chen SY.
    Chin Med J (Engl); 2009 Jul 20; 122(14):1615-20. PubMed ID: 19719960
    [Abstract] [Full Text] [Related]

  • 28. One-year atorvastatin treatment in hypercholesterolemic patients with or without carotid artery disease.
    Avellone G, Di Garbo V, Abruzzese G, Campisi D, De Simone R, Raneli G, Licata G.
    Int Angiol; 2006 Mar 20; 25(1):26-34. PubMed ID: 16520721
    [Abstract] [Full Text] [Related]

  • 29. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
    Olsson AG, Schwartz GG, Szarek M, Sasiela WJ, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A.
    Eur Heart J; 2005 May 20; 26(9):890-6. PubMed ID: 15764620
    [Abstract] [Full Text] [Related]

  • 30. Effects of modifying triglycerides and triglyceride-rich lipoproteins on cardiovascular outcomes.
    Abdel-Maksoud M, Sazonov V, Gutkin SW, Hokanson JE.
    J Cardiovasc Pharmacol; 2008 Apr 20; 51(4):331-51. PubMed ID: 18427276
    [Abstract] [Full Text] [Related]

  • 31. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ, Yellon DM.
    Heart; 2008 Jun 20; 94(6):706-14. PubMed ID: 18480348
    [Abstract] [Full Text] [Related]

  • 32. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients.
    Joy MS, Dornbrook-Lavender KA, Chin H, Hogan SL, Denu-Ciocca C.
    Ann Pharmacother; 2008 Jan 20; 42(1):9-15. PubMed ID: 18000162
    [Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
    Schwartz GG, Bolognese MA, Tremblay BP, Caplan R, Hutchinson H, Raza A, Cressman M.
    Am Heart J; 2004 Jul 20; 148(1):e4. PubMed ID: 15215813
    [Abstract] [Full Text] [Related]

  • 34. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia.
    Nordøy A, Hansen JB, Brox J, Svensson B.
    Nutr Metab Cardiovasc Dis; 2001 Feb 20; 11(1):7-16. PubMed ID: 11383326
    [Abstract] [Full Text] [Related]

  • 35. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM.
    Am J Cardiol; 2005 Aug 22; 96(4A):60E-66E. PubMed ID: 16098846
    [Abstract] [Full Text] [Related]

  • 36. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC.
    Pharmacotherapy; 1995 Aug 22; 15(3):317-37. PubMed ID: 7667166
    [Abstract] [Full Text] [Related]

  • 37. Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.
    McKenney JM.
    Postgrad Med; 2012 Jan 22; 124(1):7-20. PubMed ID: 22314110
    [Abstract] [Full Text] [Related]

  • 38. Effect of drugs on high-density lipoprotein.
    McKenney JM.
    J Clin Lipidol; 2007 Mar 22; 1(1):74-87. PubMed ID: 21291670
    [Abstract] [Full Text] [Related]

  • 39. Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype.
    Xu RX, Guo YL, Li XL, Li S, Li JJ.
    Clin Exp Pharmacol Physiol; 2014 Jul 22; 41(7):475-81. PubMed ID: 24739131
    [Abstract] [Full Text] [Related]

  • 40. Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.
    Lemieux I, Salomon H, Després JP.
    Ann Med; 2003 Jul 22; 35(6):442-8. PubMed ID: 14572169
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.